HDM 1002
Alternative Names: HDM-1002Latest Information Update: 03 Oct 2024
At a glance
- Originator Huadong Medicine
- Class Antihyperglycaemics; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
- Phase I Diabetes mellitus
Most Recent Events
- 01 Oct 2024 Hangzhou Zhongmei Huadong Pharmaceutical plans a phase I trial in Healthy volunteers in China (PO) (NCT06608329)
- 23 Sep 2024 Hangzhou Zhongmei Huadong Pharmaceutical plans a phase I Drug-Drug Interaction trial in Obesity (In adults) in China (PO) in October 2024 (NCT06601517)
- 09 Sep 2024 Hangzhou Zhongmei Huadong Pharmaceutical initiates a phase I trial in healthy volunteers in China (PO)(NCT06576401)